Compare TPVG & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | CNTN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 185.3M |
| IPO Year | 2013 | 2022 |
| Metric | TPVG | CNTN |
|---|---|---|
| Price | $4.72 | $3.18 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.90 | N/A |
| AVG Volume (30 Days) | 271.6K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.48 | $2.14 |
| 52 Week High | $7.50 | $5.27 |
| Indicator | TPVG | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 28.71 | 51.77 |
| Support Level | $4.48 | $3.04 |
| Resistance Level | $5.70 | $3.82 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 9.30 | 61.92 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.